These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 18230274)

  • 1. Pramipexole safely replaces ergot dopamine agonists with either rapid or slow switching.
    Takahashi H; Nogawa S; Tachibana H; Kawamura J; Abe T; Ogino Y; Kashihara K; Hamada T; Kowa H;
    J Int Med Res; 2008; 36(1):106-14. PubMed ID: 18230274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overnight switching from ergot-derived dopamine agonists to pramipexole in patients with Parkinson's disease: an open preliminary trial in Japan.
    Ohno H; Nakajima M; Fujioka S; Iwamoto K; Kawamura M
    J Clin Neurosci; 2009 Jun; 16(6):790-2. PubMed ID: 19286385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
    Utsumi H; Okuma Y; Kano O; Suzuki Y; Iijima M; Tomimitsu H; Hashida H; Kubo S; Suzuki M; Nanri K; Matsumura M; Murakami H; Hattori N;
    Intern Med; 2013; 52(3):325-32. PubMed ID: 23370739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
    Linazasoro G;
    Clin Neuropharmacol; 2008; 31(1):19-24. PubMed ID: 18303487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
    Linazasoro G;
    J Neurol; 2004 Mar; 251(3):335-9. PubMed ID: 15015015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
    Grosset K; Needleman F; Macphee G; Grosset D
    Mov Disord; 2004 Nov; 19(11):1370-4. PubMed ID: 15389984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Use of dopamine agonists in the treatment of Parkinson's disease].
    Gekht AB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(9):54-8. PubMed ID: 12378886
    [No Abstract]   [Full Text] [Related]  

  • 8. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
    Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG
    Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study.
    Junghanns S; Fuhrmann JT; Simonis G; Oelwein C; Koch R; Strasser RH; Reichmann H; Storch A
    Mov Disord; 2007 Jan; 22(2):234-8. PubMed ID: 17094087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transdermal Patch of Rotigotine Attenuates Freezing of Gait in Patients with Parkinson's Disease: An Open-Label Comparative Study of Three Non-Ergot Dopamine Receptor Agonists.
    Ikeda K; Hirayama T; Takazawa T; Kawabe K; Iwasaki Y
    Intern Med; 2016; 55(19):2765-2769. PubMed ID: 27725534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group.
    JAMA; 1997 Jul; 278(2):125-30. PubMed ID: 9214527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching from pergolide to pramipexole in patients with Parkinson's disease.
    Hanna PA; Ratkos L; Ondo WG; Jankovic J
    J Neural Transm (Vienna); 2001; 108(1):63-70. PubMed ID: 11261747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High doses of pergolide improve clinical global impression in advanced Parkinson's disease:- a preliminary open label study.
    Arnold G; Gasser T; Storch A; Lipp A; Kupsch A; Hundemer HP; Schwarz J
    Arch Gerontol Geriatr; 2005; 41(3):239-53. PubMed ID: 16029905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
    Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease.
    Lyons KE; Pahwa R
    Mov Disord; 2009 Oct; 24(14):2121-7. PubMed ID: 19768728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heart valve abnormalities in Parkinson's disease treated with dopamine agonists.
    Bares M; Rektorová I; Krajcovicová L; Rektor I
    J Neurol; 2008 Oct; 255(10):1596; author reply 1597. PubMed ID: 18758889
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical pharmacology of dopamine agonists in Parkinson's disease.
    Lange KW
    Drugs Aging; 1998 Nov; 13(5):381-9. PubMed ID: 9829165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of pramipexole dose-response relationships in Parkinson's disease.
    Wang Y; Sun SG; Zhu SQ; Liu CF; Liu YM; Di Q; Shang HF; Ren Y; Xiang W; Chen SD
    Drug Des Devel Ther; 2017; 11():83-89. PubMed ID: 28096656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of a once-daily extended-release formulation of pramipexole switched from an immediate-release formulation in patients with advanced Parkinson's disease: results from an open-label study.
    Takanashi M; Shimo Y; Hatano T; Oyama G; Hattori N
    Drug Res (Stuttg); 2013 Dec; 63(12):639-43. PubMed ID: 23884661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Success rate, efficacy, and safety/tolerability of overnight switching from immediate- to extended-release pramipexole in advanced Parkinson's disease.
    Schapira AH; Barone P; Hauser RA; Mizuno Y; Rascol O; Busse M; Debieuvre C; Fraessdorf M; Poewe W
    Eur J Neurol; 2013 Jan; 20(1):180-7. PubMed ID: 22845710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.